Latest Articles

Publication Date
All News Scientific
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Business Wire

Published: May 18, 2026, 10:45 a.m.
Read Full Article
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Yahoo! Finance Canada

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Yahoo! Finance …

Published: May 18, 2026, 10:45 a.m.
Read Full Article
GSK preps lawsuit against US firm AnaptysBioover endometrial cancer drug - MSN

GSK preps lawsuit against US firm AnaptysBioover endometrial cancer drug MSN

Published: May 17, 2026, 7:18 p.m.
Read Full Article
The Four Types of Therapy for Second-Line Endometrial Cancer - CancerNetwork

The Four Types of Therapy for Second-Line Endometrial Cancer CancerNetwork

Published: May 16, 2026, 2:04 p.m.
Read Full Article
Navigating the Evolving Landscape of Second-Line Endometrial Cancer Care - CancerNetwork

Navigating the Evolving Landscape of Second-Line Endometrial Cancer Care CancerNetwork

Published: May 15, 2026, 2:05 p.m.
Read Full Article
Karyopharm Therapeutics Reports Q1 2026 Results, Advances Selinexor Phase 3 Trials in Myelofibrosis and Endometrial Cancer - Minichart

Karyopharm Therapeutics Reports Q1 2026 Results, Advances Selinexor Phase 3 Trials in Myelofibrosis and Endometrial Cancer Minichart

Published: May 14, 2026, 4:30 p.m.
Read Full Article
Karyopharm completes endometrial cancer trial enrollment - Investing.com

Karyopharm completes endometrial cancer trial enrollment Investing.com

Published: May 14, 2026, 11:52 a.m.
Read Full Article
Karyopharm completes endometrial cancer trial enrollment By Investing.com - Investing.com Canada

Karyopharm completes endometrial cancer trial enrollment By Investing.com Investing.com Canada

Published: May 14, 2026, 11:45 a.m.
Read Full Article
Phase 3 endometrial cancer trial enrollment wraps as Q1 revenue hits $35.1M - Stock Titan

Phase 3 endometrial cancer trial enrollment wraps as Q1 revenue hits $35.1M Stock Titan

Published: May 14, 2026, 11:30 a.m.
Read Full Article
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment - PR Newswire

Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment PR Newswire

Published: May 14, 2026, 11:30 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!